scholarly journals The Wnt–β-Catenin–IL-10 Signaling Axis in Intestinal APCs Protects Mice from Colitis-Associated Colon Cancer in Response to Gut Microbiota

2020 ◽  
Vol 205 (8) ◽  
pp. 2265-2275
Author(s):  
Daniel Swafford ◽  
Arulkumaran Shanmugam ◽  
Punithavathi Ranganathan ◽  
Indumathi Manoharan ◽  
Mohamed S. Hussein ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Gut Microbiota ◽  
Signaling Axis

scholarly journals SYK-CARD9 Signaling Axis Promotes Gut Fungi-Mediated Inflammasome Activation to Restrict Colitis and Colon Cancer

Immunity ◽  
2018 ◽  
Vol 49 (3) ◽  
pp. 515-530.e5 ◽  
Author(s):  
Ankit Malik ◽  
Deepika Sharma ◽  
R.K. Subbarao Malireddi ◽  
Clifford S. Guy ◽  
Ti-Cheng Chang ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Inflammasome Activation ◽  
Signaling Axis

scholarly journals Probiotics and Colon Cancer

2019 ◽  
Vol 7 (3) ◽  
pp. 66 ◽  
Author(s):  
Lorenzo Drago
Keyword(s):  
Colon Cancer ◽  
Radiation Therapy ◽  
Gastrointestinal Tract ◽  
Gut Microbiota ◽  
Immune Modulation ◽  
Average Frequency ◽  
Scientific Interest ◽  
Positive Action ◽  
Bowel Movements ◽  
The Relationship

Literature has recently highlighted the enormous scientific interest on the relationship between the gut microbiota and colon cancer, and how the use of some selected probiotics can have a future impact on the adverse events which occur during this disease. Although there is no clear evidence to claim that probiotics are effective in people with cancer, recent reviews have found that probiotics can significantly reduce the incidence of diarrhea and the average frequency of daily bowel movements. However, most of this evidence needs to be more clinically convincing and further discussed. Undoubtedly, some probiotics, when properly dosed and administered, can have a strong rebalance effect on the gut microbiota and as a consequence a possible positive action on immune modulation of the gastrointestinal tract and on inflammation of the intestinal mucosa. Many recent findings indeed support the hypothesis that the daily use of some selected probiotics can be a feasible approach to effectively protect patients against the risk of some severe consequences due to radiation therapy or chemotherapy. This paper aims to review the most recent articles in order to consider a possible adjuvant approach for the use of certain well-balanced probiotics to help prevent colon cancer and the adverse effects caused by related therapies.

scholarly journals The miR-371∼373 Cluster Represses Colon Cancer Initiation and Metastatic Colonization by Inhibiting the TGFBR2/ID1 Signaling Axis

2018 ◽  
Vol 78 (14) ◽  
pp. 3793-3808 ◽  
Author(s):  
Pit Ullmann ◽  
Fabien Rodriguez ◽  
Martine Schmitz ◽  
Steffen K. Meurer ◽  
Komal Qureshi-Baig ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Metastatic Colonization ◽  
Cancer Initiation ◽  
Signaling Axis

scholarly journals Inhibitory Effects of Apigenin on Tumor Carcinogenesis by Altering the Gut Microbiota

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Shichang Bian ◽  
Hongjuan Wan ◽  
Xinyan Liao ◽  
Weisheng Wang
Keyword(s):  
Colon Cancer ◽  
Treatment Group ◽  
16S Rrna ◽  
Gut Microbiota ◽  
High Throughput Sequencing ◽  
Potential Mechanism ◽  
Inhibitory Effects ◽  
Antitumor Effects

The flavonoid apigenin is common to many plants. Although the responsible mechanisms have yet to be elucidated, apigenin demonstrates tumor suppression in vitro and in vivo. This study uses an azoxymethane (AOM)/dextran sodium sulfate- (DSS-) induced colon cancer mouse model to investigate apigenin’s potential mechanism of action exerted through its effects upon gut microbiota. The size and quantity of tumors were reduced significantly in the apigenin treatment group. Using 16S rRNA high-throughput sequencing of fecal samples, the composition of gut microbiota was significantly affected by apigenin. Further experiments in which gut microbiota were reduced and feces were transplanted provided further evidence of apigenin-modulated gut microbiota exerting antitumor effects. Apigenin was unable to reduce the number or size of tumors when gut microbiota were depleted. Moreover, tumor inhibition effects were initiated following the transplant of feces from mice treated with apigenin. Our findings suggest that the effect of apigenin on the composition of gut microbiota can suppress tumors.

628 – Identification of Crosstalk Between Gut Microbiota, Ceacams, and TGF-Β Signaling in Processing Chemotherapy Response in Colon Cancer

2019 ◽  
Vol 156 (6) ◽  
pp. S-132
Author(s):  
Shoujun Gu ◽  
Shuyun Rao ◽  
Charles H. King ◽  
Yunxiao Meng ◽  
Wilma Jogunoori ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Gut Microbiota ◽  
Chemotherapy Response

scholarly journals Shaping functional gut microbiota using dietary bioactives to reduce colon cancer risk

2017 ◽  
Vol 46 ◽  
pp. 191-204 ◽  
Author(s):  
Derek V. Seidel ◽  
M. Andrea Azcárate-Peril ◽  
Robert S. Chapkin ◽  
Nancy D. Turner
Keyword(s):  
Colon Cancer ◽  
Cancer Risk ◽  
Gut Microbiota ◽  
Colon Cancer Risk

scholarly journals The Role of the Gut Microbiome in Colorectal Cancer

2018 ◽  
Vol 31 (03) ◽  
pp. 192-198 ◽  
Author(s):  
Grace Chen
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Microbial Community ◽  
Gut Microbiota ◽  
Gut Microbiome ◽  
Intestinal Health ◽  
Genotoxic Effects ◽  
Bacterial Populations ◽  
Health And Disease

AbstractThere is increasing evidence that the gut microbiome, which consists of trillions of microbes representing over 1,000 species of bacteria with over 3 million genes, significantly impacts intestinal health and disease. The gut microbiota not only is capable of promoting intestinal homeostasis and antitumor responses but can also contribute to chronic dysregulated inflammation as well as have genotoxic effects that lead to carcinogenesis. Whether the gut microbiota maintains health or promotes colon cancer may ultimately depend on the composition of the gut microbiome and the balance within the microbial community of protective and detrimental bacterial populations. Disturbances in the normal balanced state of a healthful microbiome, known as dysbiosis, have been observed in patients with colorectal cancer (CRC); however, whether these alterations precede and cause CRC remains to be determined. Nonetheless, studies in mice strongly suggest that the gut microbiota can modulate susceptibility to CRC, and therefore may serve as both biomarkers and therapeutic targets.

Sign in / Sign up

Export Citation Format

Share Document